Chandra Belani, MD - Penn State Cancer Institute
Researcher Profile
Chandra Belani, MD
Professor, Department of Medicine
Division of Hematology and Oncology
Division of Hematology and Oncology
Scientific Program:Next-Generation Therapies
Disease Teams:
Cancer Institute, Thoracic Cancer Team
Research Interests
- Non-Small Cell Lung Carcinoma
- Therapeutics
- Neoplasms
- Paclitaxel
- Survival
- Carboplatin
- Drug Therapy
- Lung Neoplasms
- Docetaxel
- Radiotherapy
- Cisplatin
- Pharmacokinetics
Clinical Trials
Oncogenic Mutations/Gene Rearrangements in Patients with Advanced Adenocarcinoma Lung
One Time Tissue and Blood Collection from Patients with Lung Cancer at Risk for Developing Lung Cancer
Recent Publications
2023
Malhotra, MK, Pahuja, S, Kiesel, BF, Appleman, LJ, Ding, F, Lin, Y, Tawbi, HA, Stoller, RG, Lee, JJ, Belani, CP, Chen, AP, Giranda, VL, Shepherd, SP, Emens, LA, Ivy, SP, Chu, E, Beumer, JH & Puhalla, S 2023, 'A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)', Breast Cancer Research and Treatment, vol. 198, no. 3, pp. 487-498. https://doi.org/10.1007/s10549-023-06889-0
Rice, SJ & Belani, CP 2023, 'Design of experiments approach for systematic optimization of a single-shot diaPASEF plasma proteomics workflow applicable for high-throughput', Proteomics - Clinical Applications. https://doi.org/10.1002/prca.202300006
Adishesha, AS, Jakielaszek, L, Azhar, F, Zhang, P, Honavar, V, Ma, F, Belani, C, Mitra, P & Huang, SX 2023, 'Forecasting User Interests Through Topic Tag Predictions in Online Health Communities', IEEE Journal of Biomedical and Health Informatics, vol. 27, no. 7, pp. 3645-3656. https://doi.org/10.1109/JBHI.2023.3271580
2022
Piha-Paul, S, Simon, G, Belani, CP, Chao, H, Gaspar, K, Lee, B & Dowlati, A 2022, 'A Phase 1, Open-Label, Dose-Escalation Study of L-DOS47 in Combination With Pemetrexed Plus Carboplatin in Patients With Stage IV Recurrent or Metastatic Nonsquamous NSCLC', JTO Clinical and Research Reports, vol. 3, no. 11, 100408. https://doi.org/10.1016/j.jtocrr.2022.100408
Varlotto, JM, Sun, Z, Ky, B, Upshaw, J, Fitzgerald, TJ, Diehn, M, Lovly, C, Belani, C, Oettel, K, Masters, G, Harkenrider, M, Ross, H, Ramalingam, S & Pennell, NA 2022, 'A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181', Clinical Lung Cancer, vol. 23, no. 7, pp. 547-560. https://doi.org/10.1016/j.cllc.2022.06.005
ETCTN-8282 study team 2022, 'A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer', Cancer Chemotherapy and Pharmacology, vol. 89, no. 5, pp. 721-735. https://doi.org/10.1007/s00280-022-04430-6
Rice, SJ & Belani, CP 2022, 'Optimizing data-independent acquisition (DIA) spectral library workflows for plasma proteomics studies', Proteomics, vol. 22, no. 17, 2200125. https://doi.org/10.1002/pmic.202200125
Shen, C, Holguin, RAP, Schaefer, E, Zhou, S, Belani, CP, Ma, PC & Reed, MF 2022, 'Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma', BMC health services research, vol. 22, no. 1, 470. https://doi.org/10.1186/s12913-022-07857-y
2021
Varlotto, JM, Sun, Z, Ky, B, Upshaw, J, Katz, SI, Fitzgerald, TJ, Wakelee, H, Diehn, M, Mankoff, DA, Lovely, C, Belani, C, Oettel, K, Masters, G, Ramalingam, S & Pennell, NA 2021, 'A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study', Oncologist, vol. 26, no. 6, pp. 523-532. https://doi.org/10.1002/onco.13725
Rice, SJ & Belani, CP 2021, 'Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancer', PloS one, vol. 16, no. 12 December, e0260988. https://doi.org/10.1371/journal.pone.0260988
Rolfo, C, Mack, P, Scagliotti, GV, Aggarwal, C, Arcila, ME, Barlesi, F, Bivona, T, Diehn, M, Dive, C, Dziadziuszko, R, Leighl, N, Malapelle, U, Mok, T, Peled, N, Raez, LE, Sequist, L, Sholl, L, Swanton, C, Abbosh, C, Tan, D, Wakelee, H, Wistuba, I, Bunn, R, Freeman-Daily, J, Wynes, M, Belani, C, Mitsudomi, T & Gandara, D 2021, 'Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer', Journal of Thoracic Oncology, vol. 16, no. 10, pp. 1647-1662. https://doi.org/10.1016/j.jtho.2021.06.017
2020
Sang, M, Rice, S, Jiang, L, Liu, X, Gragnoli, C, Belani, CP & Wu, R 2020, 'A rewiring model of intratumoral interaction networks', Computational and Structural Biotechnology Journal, vol. 18, pp. 45-51. https://doi.org/10.1016/j.csbj.2019.11.009
Rice, SJ, Hyland, V, Behera, M, Ramalingam, SS, Bunn, P & Belani, CP 2020, 'Guidance on the Clinical Management of Electronic Cigarette or Vaping-Associated Lung Injury', Journal of Thoracic Oncology, vol. 15, no. 11, pp. 1727-1737. https://doi.org/10.1016/j.jtho.2020.08.012
Rice, SJ, Liu, X, Hyland, V, Liu, Z & Belani, CP 2020, 'Mutations in genes connected with the TCF7L2 transcription factor are associated with a poor prognosis in non-small cell lung cancer', Lung Cancer, vol. 141, pp. 97-100. https://doi.org/10.1016/j.lungcan.2020.01.015
C14018 study investigators 2020, 'Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses', Journal of Thoracic Oncology, vol. 15, no. 2, pp. 274-287. https://doi.org/10.1016/j.jtho.2019.10.013
Smeltzer, MP, Wynes, MW, Lantuejoul, S, Soo, R, Ramalingam, SS, Varella-Garcia, M, Meadows Taylor, M, Richeimer, K, Wood, K, Howell, KE, Dalurzo, ML, Felip, E, Hollenbeck, G, Kerr, K, Kim, ES, Mathias, C, Pacheco, J, Postmus, P, Powell, C, Tsuboi, M, Wistuba, II, Wakelee, HA, Belani, CP, Scagliotti, GV & Hirsch, FR 2020, 'The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer', Journal of Thoracic Oncology, vol. 15, no. 9, pp. 1434-1448. https://doi.org/10.1016/j.jtho.2020.05.002
Dingemans, AMC, Soo, RA, Jazieh, AR, Rice, SJ, Kim, YT, Teo, LLS, Warren, GW, Xiao, SY, Smit, EF, Aerts, JG, Yoon, SH, Veronesi, G, De Cobelli, F, Ramalingam, SS, Garassino, MC, Wynes, MW, Behera, M, Haanen, J, Lu, S, Peters, S, Ahn, MJ, Scagliotti, GV, Adjei, AA & Belani, CP 2020, 'Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic', Journal of Thoracic Oncology, vol. 15, no. 7, pp. 1119-1136. https://doi.org/10.1016/j.jtho.2020.05.001
Behera, M, Steuer, CE, Liu, Y, Fernandez, F, Fu, C, Higgins, KA, Gillespie, TW, Pakkala, S, Pillai, RN, Force, S, Belani, CP, Khuri, FR, Curran, WJ & Ramalingam, SS 2020, 'Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database Analysis', Oncologist, vol. 25, no. 6, pp. e964-e975. https://doi.org/10.1634/theoncologist.2019-0661
2019
Takebe, N, Beumer, JH, Kummar, S, Kiesel, BF, Dowlati, A, O'Sullivan Coyne, G, Piekarz, R, Rubinstein, L, Fogli, LK, Vaishampayan, U, Goel, S, O'Bryant, CL, El-Rayes, BF, Chung, V, Lenz, HJ, Kim, R, Belani, CP, Tuscano, JM, Schelman, W, Moore, N, Doroshow, JH & Chen, AP 2019, 'A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction', British Journal of Clinical Pharmacology, vol. 85, no. 11, pp. 2499-2511. https://doi.org/10.1111/bcp.14054
Rice, SJ, Liu, X, Zhang, J & Belani, CP 2019, 'Absolute Quantification of All Identified Plasma Proteins from SWATH Data for Biomarker Discovery', Proteomics, vol. 19, no. 3, 1800135. https://doi.org/10.1002/pmic.201800135
Rice, SJ, Liu, X, Zhang, J, Jia, B, Zheng, H & Belani, CP 2019, 'Advanced NSCLC patients with high IL-6 levels have altered peripheral T cell population and signaling', Lung Cancer, vol. 131, pp. 58-61. https://doi.org/10.1016/j.lungcan.2019.03.014
Rice, SJ, Liu, X, Wang, HG & Belani, CP 2019, 'EGFR mutations and AKT phosphorylation are markers for sensitivity to combined MCL-1 and BCL-2/xL inhibition in non-small cell lung cancer', PloS one, vol. 14, no. 5, e0217657. https://doi.org/10.1371/journal.pone.0217657
Videtic, GM, Paulus, R, Singh, AK, Chang, JY, Parker, W, Olivier, KR, Timmerman, RD, Komaki, RR, Urbanic, JJ, Stephans, KL, Yom, SS, Robinson, CG, Belani, CP, Iyengar, P, Ajlouni, MI, Gopaul, DD, Gomez Suescun, JB, McGarry, RC, Choy, H & Bradley, JD 2019, 'Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer', International Journal of Radiation Oncology Biology Physics, vol. 103, no. 5, pp. 1077-1084. https://doi.org/10.1016/j.ijrobp.2018.11.051
Yin, R, Rice, SJ, Wang, J, Gao, L, Tsai, J, Anvari, RT, Zhou, F, Liu, X, Wang, G, Tang, Y, Jr, MCM, Belani, CP, Chen, DB, Nelson, JS & Tan, W 2019, 'Membrane trafficking and exocytosis are upregulated in port wine stain blood vessels', Histology and histopathology, vol. 34, no. 5, pp. 479-490. https://doi.org/10.14670/HH-18-051
Ramalingam, SS, Dahlberg, SE, Belani, CP, Saltzman, JN, Pennell, NA, Nambudiri, GS, McCann, JC, Winegarden, JD, Kassem, MA, Mohamed, MK, Rothman, JM, Lyss, AP, Horn, L, Stinchcombe, TE & Schiller, JH 2019, 'Pemetrexed, bevacizumab, or the combination as maintenance therapy for advanced nonsquamous non–small-cell lung cancer: ECOG-ACRIN 5508', Journal of Clinical Oncology, vol. 37, no. 26, pp. 2360-2367. https://doi.org/10.1200/JCO.19.01006
Appleman, LJ, Beumer, JH, Jiang, Y, Lin, Y, Ding, F, Puhalla, S, Swartz, L, Owonikoko, TK, Donald Harvey, R, Stoller, R, Petro, DP, Tawbi, HA, Argiris, A, Strychor, S, Pouquet, M, Kiesel, B, Chen, AP, Gandara, D, Belani, CP, Chu, E & Ramalingam, SS 2019, 'Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies', Cancer Chemotherapy and Pharmacology, vol. 84, no. 6, pp. 1289-1301. https://doi.org/10.1007/s00280-019-03960-w
Reckamp, KL, Frankel, PH, Ruel, N, Mack, PC, Gitlitz, BJ, Li, T, Koczywas, M, Gadgeel, SM, Cristea, MC, Belani, CP, Newman, EM, Gandara, DR & Lara, PN 2019, 'Phase II trial of cabozantinib plus erlotinib in patients with advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer with progressive disease on epidermal growth factor receptor tyrosine kinase inhibitor therapy: A California cancer consortium phase II trial (NCI 9303)', Frontiers in Oncology, vol. 9, no. MAR, 132. https://doi.org/10.3389/fonc.2019.00132
CASSINI Investigators 2019, 'Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer', New England Journal of Medicine, vol. 380, no. 8, pp. 720-728. https://doi.org/10.1056/NEJMoa1814630
Tian, S, Zhang, X, Jiang, R, Pillai, RN, Owonikoko, TK, Steuer, CE, Saba, NF, Pakkala, S, Patel, PR, Belani, CP, Khuri, FR, Curran, WJ, Ramalingam, SS, Behera, M & Higgins, KA 2019, 'Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer Database', Clinical Lung Cancer, vol. 20, no. 6, pp. 484-493.e6. https://doi.org/10.1016/j.cllc.2019.06.014